Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: A translational pharmacokinetic-pharmacodynamic modeling study

Kendra K. Radtke, Jacqueline P. Ernest, Nan Zhang, Nicole C. Ammerman, Eric Nuermberger, Robert Belknap, Rosanna Boyd, Timothy R. Sterling, Rada M. Savic*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Rifapentine has facilitated treatment shortening for latent tuberculosis infection (LTBI) in combination with isoniazid once weekly for 3 months (3HP) or daily for 1 month (1HP). Our objective was to determine the optimal rifapentine dose for a 6-week monotherapy regimen (6wP) and predict clinical efficacy. Rifapentine and isoniazid pharmacokinetics were simulated in mice and humans. Mouse lung CFU data were used to characterize exposure-response relationships of 1HP, 3HP, and 6wP and translated to predict clinical efficacy. A 600-mg daily dose for 6wP delivered greater cumulative rifapentine exposure than 1HP or 3HP. The maximum regimen effect (Emax) was 0.24 day21. The regimen potencies, measured as the concentration at 50% of Emax (EC50), were estimated to be 2.12 mg/liter for 3HP, 3.72 mg/liter for 1HP, and 4.71 mg/liter for 6wP, suggesting that isoniazid contributes little to 1HP efficacy. Clinical translation predicted that 6wP reduces bacterial loads at a higher rate than 3HP and to a greater extent than 3HP and 1HP. 6wP (600 mg daily) is predicted to result in equal or better efficacy than 1HP and 3HP for LTBI treatment without the potential added toxicity of isoniazid. Results from ongoing and future clinical studies will be required to support these findings.

Original languageEnglish
Article numbere01705-21
JournalAntimicrobial Agents and Chemotherapy
Volume65
Issue number12
DOIs
Publication statusPublished - 17 Nov 2021

Fingerprint

Dive into the research topics of 'Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: A translational pharmacokinetic-pharmacodynamic modeling study'. Together they form a unique fingerprint.

Cite this